中国P站

Gut microbiota; Mucosal immunity; Inflammatory diseases; Autoimmune disorders; Dysbiosis; Immune modulation

Introduction

The human gastrointestinal tract harbors a diverse and dynamic microbial ecosystem, collectively known as the gut microbiota, which is essential for maintaining immune homeostasis. The mucosal immune system, comprising epithelial barriers, innate immune responses, and adaptive immunity, continuously interacts with this microbial community [1]. These interactions are critical for immune tolerance, protection against pathogens, and the prevention of aberrant immune responses.

Recent studies have elucidated how gut microbiota modulates immune functions, influencing inflammatory diseases and autoimmune disorders. In a healthy state, commensal microbes stimulate immune regulatory pathways, promoting anti-inflammatory cytokine production and maintaining epithelial integrity. However, disruptions in microbial composition—termed dysbiosis—can lead to excessive immune activation and chronic inflammation [2]. This dysbiosis has been associated with several autoimmune and inflammatory conditions, including IBD, multiple sclerosis, and systemic lupus erythematosus.

Microbial-derived metabolites such as short-chain fatty acids (SCFAs) and tryptophan derivatives play key roles in shaping mucosal immunity. SCFAs enhance regulatory T-cell function, while microbial-derived signals influence the production of antimicrobial peptides and mucosal barrier integrity [3]. The recognition of microbial-associated molecular patterns (MAMPs) by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), further modulates immune responses. Dysregulated interactions between PRRs and gut microbiota have been implicated in the pathogenesis of inflammatory and autoimmune diseases.

Given the growing understanding of gut microbiota’s role in immune modulation, therapeutic strategies targeting microbial composition have gained attention. Probiotics, prebiotics, dietary modifications, and fecal microbiota transplantation are being explored as potential interventions to restore immune balance. Despite promising findings, challenges remain in identifying specific microbial signatures and their mechanistic roles in disease progression [4]. This review aims to explore the interplay between gut microbiota and mucosal immunity, highlighting implications for inflammatory diseases and autoimmune disorders. By understanding these interactions, therapeutic approaches can be developed to modulate immune responses and improve disease outcomes.

Methods

This review was conducted by systematically analyzing peer-reviewed literature on gut microbiota, mucosal immunity, inflammatory diseases, and autoimmune disorders. Scientific databases, including PubMed, Scopus, and Web of Science, were searched using relevant keywords. Studies published within the last decade were prioritized to ensure contemporary relevance.

Inclusion criteria consisted of original research, clinical trials, and high-impact review articles exploring microbial-immune interactions [5]. Studies focusing on human subjects or relevant animal models were included. Exclusion criteria involved studies with inconclusive findings or those lacking direct relevance to gut microbiota and immune modulation.

Data synthesis involved categorizing findings based on microbial composition, immune regulatory mechanisms, and disease associations. A comparative analysis was conducted to highlight consistencies and discrepancies in research findings. Potential therapeutic implications of microbiota-targeted interventions were also evaluated. This approach allowed for a comprehensive understanding of the impact of gut microbiota on mucosal immunity and its relevance to disease pathogenesis [6].

Results

Research indicates that gut microbiota exerts profound effects on mucosal immunity through microbial-derived metabolites, PRR signaling, and immune cell modulation. SCFAs, particularly butyrate, play a significant role in promoting regulatory T-cell differentiation, enhancing mucosal barrier integrity, and reducing pro-inflammatory cytokine production. Conversely, microbial dysbiosis is linked to increased intestinal permeability, immune activation, and chronic inflammation.

Studies on IBD have identified a reduction in beneficial microbial species, such as Faecalibacterium prausnitzii, and an increase in pro-inflammatory bacteria like Escherichia coli. Similarly, autoimmune diseases such as rheumatoid arthritis and type 1 diabetes have been associated with distinct microbial signatures and altered immune responses.

Clinical trials assessing probiotic and prebiotic supplementation have demonstrated potential in modulating immune responses. Fecal microbiota transplantation has shown promise in restoring microbial diversity and improving disease symptoms. However, variability in individual responses highlights the need for personalized therapeutic strategies.

Discussion

The intricate relationship between gut microbiota and mucosal immunity underscores the importance of maintaining microbial balance for immune homeostasis. Dysbiosis contributes to inflammatory and autoimmune diseases by disrupting epithelial barriers and promoting aberrant immune activation. Identifying microbial signatures associated with disease onset and progression can enhance diagnostic and therapeutic strategies [7].

Therapeutic interventions targeting the gut microbiota show promise, but challenges remain in standardizing treatment approaches. Probiotics and prebiotics offer potential benefits but require further research to determine optimal strains, dosages, and long-term effects [8]. Fecal microbiota transplantation, although effective in some conditions, requires refinement to ensure safety and efficacy.

Future research should focus on elucidating precise microbial-host interactions, leveraging metagenomic and metabolomic analyses to develop targeted therapies. Personalized medicine approaches may improve treatment outcomes by tailoring microbial interventions based on individual microbiota profiles.

Conclusion

The interplay between mucosal immunity and gut microbiota has significant implications for inflammatory diseases and autoimmune disorders. Maintaining microbial balance is essential for immune homeostasis, while dysbiosis contributes to disease pathogenesis. Understanding microbial-immune interactions can inform therapeutic strategies to modulate immune responses and improve patient outcomes.

Advances in microbiota-targeted interventions, including probiotics, prebiotics, and fecal microbiota transplantation, offer promising avenues for disease management. However, further research is needed to optimize these approaches and develop personalized treatment strategies. By integrating microbial and immunological insights, therapeutic paradigms can be established to mitigate inflammation and restore immune balance.

References

1. Latz E, Xiao TS, Stutz A (2013) . Nat Rev Immunol 13: 397-411.

   , ,

2. Miao EA, Rajan JV, Aderem A (2011) . Immunol Rev 243: 206-214.

   , ,

3. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, et al. (2000) . Immunity 12: 581-590.

   , ,

4. Vajjhala PR, Mirams RE, Hill JM (2012) . J Biol Chem 287: 41732-41743.

   , ,

5. Proell M, Gerlic M, Mace PD, Reed JC, Riedl SJ (2013) . Biochem J 449: 613-621.

   , ,

6. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, et al. (2008) . Immunity 28: 285-287.

   , ,

7. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, et al. (2007) . Cell Death Differ 14: 1590-1604.

   , ,

8. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) . Nat Immunol 7: 1250-1257.

   , ,